2012-press-releases
15 May 2012
CAPITAL MARKETS DAY, OSLO, 30 May
Please join the management team of Clavis Pharma (OSE: CLAVIS) and expert speakers, Dr. Oliver G. Ottmann, Dr. Emmet McCormack and Dr. David Cotterell for an in-depth overview of the Company’s clinical projects and its Lipid Vector Technology.
CAPITAL MARKETS DAY, OSLO, 30 May
Please join the management team of Clavis Pharma (OSE: CLAVIS) and expert speakers, Dr. Oliver G. Ottmann, Dr. Emmet McCormack and Dr. David Cotterell for an in-depth overview of the Company’s clinical projects and its Lipid Vector Technology.
14 May 2012
CAPITAL MARKETS DAY, NYC, 23 MAY
Please join the management team of Clavis Pharma (OSE: CLAVIS) and expert speakers, Dr. Farhad Ravandi and Dr. Jennifer Spratlin, for an in-depth overview of the Company's clinical projects and its Lipid Vector Technology.
CAPITAL MARKETS DAY, NYC, 23 MAY
Please join the management team of Clavis Pharma (OSE: CLAVIS) and expert speakers, Dr. Farhad Ravandi and Dr. Jennifer Spratlin, for an in-depth overview of the Company's clinical projects and its Lipid Vector Technology.
26 April 2012
Clavis Pharma - First Quarter 2012 Results
Clavis Pharma ASA (OSE: CLAVIS), the Norwegian cancer drug development company, announces today its results for the first quarter 2012 (period ended March 31, 2012). A presentation to investors, analysts and the press will take place in Oslo at 08:30 CET, see below for details.
Clavis Pharma - First Quarter 2012 Results
Clavis Pharma ASA (OSE: CLAVIS), the Norwegian cancer drug development company, announces today its results for the first quarter 2012 (period ended March 31, 2012). A presentation to investors, analysts and the press will take place in Oslo at 08:30 CET, see below for details.
26 April 2012
2011 Annual Report for Clavis Pharma ASA
Clavis Pharma ASA (OSE: CLAVIS): Reference is made to the stock exchange announcement dated 30 March 2012 regarding the approval of Clavis Pharma’s Annual Financial Statements for 2011. Please find attached the complete Annual Report for 2011.
2011 Annual Report for Clavis Pharma ASA
Clavis Pharma ASA (OSE: CLAVIS): Reference is made to the stock exchange announcement dated 30 March 2012 regarding the approval of Clavis Pharma’s Annual Financial Statements for 2011. Please find attached the complete Annual Report for 2011.
26 April 2012
Join Clavis Pharma at their Capital Markets Days in NYC, USA, and Oslo, Norway
Clavis Pharma ASA (OSE: CLAVIS), the cancer-focused drug development company, is hosting Capital Markets Days for members of the financial community, press and other interested parties, in New York City, USA and Oslo, Norway in May.
Join Clavis Pharma at their Capital Markets Days in NYC, USA, and Oslo, Norway
Clavis Pharma ASA (OSE: CLAVIS), the cancer-focused drug development company, is hosting Capital Markets Days for members of the financial community, press and other interested parties, in New York City, USA and Oslo, Norway in May.
19 April 2012
Invitation to presentation and webcast of Clavis Pharma's first quarter results 2012
Clavis Pharma ASA (OSE: CLAVIS) presents the company's first quarter 2012 results on Thursday 26 April 2012 at Hotel Continental, Stortingsgaten 24/26, Oslo, Norway.
Invitation to presentation and webcast of Clavis Pharma's first quarter results 2012
Clavis Pharma ASA (OSE: CLAVIS) presents the company's first quarter 2012 results on Thursday 26 April 2012 at Hotel Continental, Stortingsgaten 24/26, Oslo, Norway.
26 March 2012
Clavis Pharma – Update on Phase III CLAVELA Study
Clavis Pharma ASA (OSE: CLAVIS), the Norwegian cancer drug development company, announces that, in reference to its announcement on 17 January 2012, the first batch of elacytarabine from its new manufacturer, Baxter Oncology GmbH (Germany), has been released and is now available for clinical use.
Clavis Pharma – Update on Phase III CLAVELA Study
Clavis Pharma ASA (OSE: CLAVIS), the Norwegian cancer drug development company, announces that, in reference to its announcement on 17 January 2012, the first batch of elacytarabine from its new manufacturer, Baxter Oncology GmbH (Germany), has been released and is now available for clinical use.
26 March 2012
Enrolment Target of 360 Patients Reached in Pivotal LEAP Trial of CP-4126 versus Gemcitabine in Metastatic Pancreatic Cancer
Clavis Pharma ASA (OSE: CLAVIS), the Norwegian cancer drug development company, announces today that its partner Clovis Oncology, Inc. (NASDAQ: CLVS) has reached the enrolment target in the pivotal LEAP study of CP-4126 (also known as CO-101) in patients with metastatic pancreatic cancer. CP-4126 is the Company’s lipid-conjugated form of the anti-cancer drug gemcitabine.
Enrolment Target of 360 Patients Reached in Pivotal LEAP Trial of CP-4126 versus Gemcitabine in Metastatic Pancreatic Cancer
Clavis Pharma ASA (OSE: CLAVIS), the Norwegian cancer drug development company, announces today that its partner Clovis Oncology, Inc. (NASDAQ: CLVS) has reached the enrolment target in the pivotal LEAP study of CP-4126 (also known as CO-101) in patients with metastatic pancreatic cancer. CP-4126 is the Company’s lipid-conjugated form of the anti-cancer drug gemcitabine.
21 March 2012
Presentation at the Carnegie Nordic Healthcare Seminar 2012
Clavis Pharma ASA (OSE: CLAVIS), the Norwegian cancer drug development company, announces that the CEO, Olav Hellebø, will give a company presentation to investors at the Carnegie Nordic Healthcare Seminar tomorrow at 09:05 (CET) in Stockholm, Sweden
Presentation at the Carnegie Nordic Healthcare Seminar 2012
Clavis Pharma ASA (OSE: CLAVIS), the Norwegian cancer drug development company, announces that the CEO, Olav Hellebø, will give a company presentation to investors at the Carnegie Nordic Healthcare Seminar tomorrow at 09:05 (CET) in Stockholm, Sweden
8 February 2012
Fourth Quarter Results 2011
Clavis Pharma ASA (OSE: CLAVIS); the Norwegian cancer drug development company, announces today its results for the fourth quarter 2011 (period ended December 31, 2011). A presentation to investors, analysts and the press will take place in Oslo at 08:30 CET, see below for details.
Fourth Quarter Results 2011
Clavis Pharma ASA (OSE: CLAVIS); the Norwegian cancer drug development company, announces today its results for the fourth quarter 2011 (period ended December 31, 2011). A presentation to investors, analysts and the press will take place in Oslo at 08:30 CET, see below for details.